Intec Pharma Ltd. | Balance Sheet

Fiscal year is January-December. All values ILS Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
29,700.00
30,399.00
119,924.00
70,391.80
191,697.60
40,579
Total Accounts Receivable
1,862.00
1,021.00
3,044.00
2,774.90
1,659.40
2,031
Other Current Assets
721.00
99.00
6,167.00
6,400.30
2,246.20
955
Total Current Assets
32,283.00
31,519.00
129,135.00
79,567.00
195,603.20
43,565
Net Property, Plant & Equipment
14,991.00
17,101.00
15,906.00
15,575.50
28,488.40
12,233
Total Investments and Advances
210.00
-
-
-
-
-
Total Assets
47,484.00
48,620.00
145,041.00
95,142.50
224,091.50
61,510
Accounts Payable
1,323.00
-
2,394.00
4,433.60
6,436.40
Other Current Liabilities
3,600.00
7,219.00
2,731.00
2,955.80
13,515.10
Total Current Liabilities
4,923.00
7,219.00
5,125.00
7,389.40
19,951.60
Other Liabilities
10,298.00
4,528.00
1,277.00
373.30
-
Total Liabilities
15,221.00
11,747.00
6,402.00
7,762.70
19,951.60
Common Equity (Total)
32,263.00
36,873.00
138,639.00
87,379.80
204,140.00
Total Shareholders' Equity
32,263.00
36,873.00
138,639.00
87,379.80
204,140.00
Total Equity
32,263.00
36,873.00
138,639.00
87,379.80
204,140.00
Liabilities & Shareholders' Equity
47,484.00
48,620.00
145,041.00
95,142.50
224,091.50

About Intec Pharma

View Profile
Address
RMPE Building
Jerusalem JM 9777512
Israel
Employees -
Website http://www.intecpharma.com
Updated 07/08/2019
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which focuses on developing drugs based on its proprietary Accordion Pill platform technology. Its product pipeline includes four product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients; Accordion Pill Zaleplon, which is being developed for the treatment of insomnia, including sleep induction and the improvement of sleep maintenance; an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug which induces ulcers; and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol and tetrahydrocannabinol, which is being developed for various indications including low back neuropathic pain and fibromyalgia. The company was founded by Zvi Joseph in 2000 and is headquartered in Jerusalem, Israel.